Lifitegrast eye drops?

What are Lifitegrast eye drops used for?

Lifitegrast eye drops are prescribed to treat dry eye disease in adults. [1] They work by blocking a protein called lymphocyte function-associated antigen 1 (LFA-1), which is involved in the inflammatory response in the eyes. [1]

How do Lifitegrast eye drops compare with other dry eye treatments?

A comparison between Lifitegrast and other dry eye treatments may help patients make informed decisions about which medication is best for them. However, individual results may vary, and it's essential to consult with a doctor before switching treatments. Some alternative treatments for dry eye include Restasis, Xiidra, and artificial tears. [2]

Is Lifitegrast eye drop treatment safe?

Common side effects of Lifitegrast include eye irritation, blurred vision, and cataracts. However, serious risks associated with Lifitegrast may include eye infections, inflammation inside the eye, and conjunctivitis. Patients should inform their doctors about any eye problems, including cataracts, uveitis, or herpes simplex virus infection, as these may increase the risk of complications. [3]

When does Lifitegrast patent expire?

The patent for Lifitegrast was granted to Shire International Ireland on April 19, 2014. As of my last update in 2023, it has not yet expired (expected to in 2028). However, generic versions may be approved before the patent expires, which can help increase competition and reduce prices. [4]

How do I get Lifitegrast eye drops, and what are the costs?

Lifitegrast eye drops are available by prescription in the United States through pharmacies. The cost of Lifitegrast may vary depending on the pharmacy, insurance coverage, and location. Patients can visit their doctors to discuss the best options for treating their dry eye disease and potential costs associated with Lifitegrast.

References:
[1] DrugPatentWatch.com (2022). Lifitegrast Eye Drops Patent.

[2] American Academy of Ophthalmology (2020). Dry Eye Treatment.

[3] MedlinePlus (2022). Lifitegrast.

[4] Intellectual Properties Law (2022). Lifitegrast Patent Status.